TY  - JOUR
T1  - POtential use of γ-secretase modulators in the treatment of alzheimer disease
AU  - Wagner SL, Tanzi RE, Mobley WC, Galasko D
Y1  - 2012/10/01
N1  - 10.1001/archneurol.2012.540
JO  - Archives of Neurology
SP  - 1255
EP  - 1258
VL  - 69
IS  - 10
N2  - Athough significant progress has occurred in the past 20 years regarding our understanding of Alzheimer disease pathogenesis, we have yet to identify disease-modifying therapeutics capable of substantially altering the clinical course of this prevalent neurodegenerative disease. In this short review, we discuss 2 approaches that are currently being tested clinically (γ-secretase inhibition and γ-secretase modulation) and emphasize the significant differences between these 2 therapeutic approaches. We also discuss certain genetic- and biomarker-based translational and clinical trial paradigms that may assist in developing a useful therapeutic agent.
SN  - 0003-9942
M3  - doi: 10.1001/archneurol.2012.540
UR  - http://dx.doi.org/10.1001/archneurol.2012.540
ER  -